Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.63 |
| ▸ | GCK | P35557 | 7/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.38 |
| ▸ | APP | P05067 | 2/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2650602 | 0.90 | KCNH2 (0.52) | KCNH2GCK | |
| SCHEMBL2647441 | 0.89 | KCNH2 (0.50) | KCNH2GCKAPPPSEN1PSEN2 | |
| SCHEMBL2646723 | 0.87 | KCNH2 (0.62) | KCNH2GCKGPR119 | |
| SCHEMBL1861377 | 0.86 | KCNH2 (0.48) | KCNH2GCKAPPPSEN1PSEN2 | |
| SCHEMBL1861379 | 0.86 | KCNH2 (0.48) | KCNH2GCKAPPPSEN1PSEN2 | |
| SCHEMBL1171465 | 0.85 | KCNH2 (0.63) | KCNH2GCKAPPPSEN1PSEN2 | |
| SCHEMBL1171463 | 0.85 | KCNH2 (0.63) | KCNH2GCKAPPPSEN1PSEN2 | |
| SCHEMBL2647331 | 0.85 | KCNH2 (0.48) | KCNH2GCKAPPPSEN1PSEN2 | |
| SCHEMBL2645963 | 0.85 | KCNH2 (0.48) | KCNH2GCKAKR1C3AKR1C2APP | |
| SCHEMBL2645781 | 0.85 | KCNH2 (0.48) | KCNH2GCKAKR1C3AKR1C2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203207-A1 | Heteroaromatic glucokinase activators | BIZZARRO FRED T | 2007-08-30 | — | — | US | disclosed |
| US-7223868-B2 | Such as 2-(3-chloro-phenyl)-3-cyclopentyl-N-thiazol-2-yl-propionamide which increases insulin secretion in treatment of type II diabetes | HOFFMANN-LA ROCHE INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050261503-A1 | Heteroaromatic glucokinase activators | BIZZARO FRED T | 2005-11-24 | — | — | US | disclosed |
| US-6951945-B2 | Heteroaromatic glucokinase activators | HOFFMAN-LA ROCHE INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-20040014968-A1 | Heteroaromatic glucokinase activators | BIZZARRO FRED THOMAS (US) | 2004-01-22 | — | — | US | disclosed |
| US-6610846-B1 | Increase insulin secretion; type II diabetes; 2,3-Di-substituted N-heteroaromatic propionamides with 3- a phenyl group and 2- a methyl cycloalkyl ring; 3-cyclopentyl-2-(3,4-dichlorophenyl)-N-pyridazin-3-yl-propionamide | HOFFMAN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014968-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | KCNH2 1022/4885GCK 2/4885GPR119 7/4885 |
| US-20070203207-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | KCNH2 1022/4885GCK 2/4885GPR119 7/4885 |
| US-20050261503-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | KCNH2 1022/4885GCK 2/4885GPR119 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.